Drug Safety

, Volume 41, Issue 4, pp 325–328 | Cite as

The Safety of Generic Prescription Drugs in the United States

  • Sonal SinghEmail author


‘Then you should say what you mean,’ the March Hare went on.

‘I do,’ Alice hastily replied; ‘at least—at least I mean what I say—that’s the same thing, you know.’

‘Not the same thing a bit!’ said the Hatter. ‘You might just as well say that “I see what I eat” is the same thing as “I eat what I see”!’

‘You might just as well say,’ added the March Hare, ‘that “I like what I get” is the same thing as “I get what I like”!’

‘You might just as well say,’ added the Dormouse, who seemed to be talking in his sleep, ‘that “I breathe when I sleep” is the same thing as “I sleep when I breathe”!’

Alice in Wonderland, Chapter VII—“The Mad Tea Party”;

Lewis Carroll 1865 [1]

These lines capture the dilemma faced by patients, physicians and policy makers who grapple with the challenge of deciding whether their generic prescription drugs are like their brand name counterparts. Approximately nine out of every ten prescriptions filled in the USA constitutes a generic drug [2]. There have...


Compliance with Ethical Standards


No sources of funding were used to assist in the preparation of this commentary.

Conflicts of interest

Sonal Singh has no conflicts of interest relevant to the content of this commentary.


  1. 1.
    Caroll L. Alice in Wonderland. Project Gutenberg’s Alice’s Adventures in Wonderland, by Lewis Carroll [Internet]. 1865. Accessed 11 Dec 2017.
  2. 2.
    Association GP. Generic drugs savings in the US 2015 Seventh Annual Edition: Accessed 11 Dec 2017.
  3. 3.
    Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Katie T. Generic A.D.H.D drug, not equivalent to the brand, is in use anway. New York Times. 2015. Accessed 11 Dec 2017.
  5. 5.
    Park-Wyllie L, van Stralen J, Castillon G, Sherman SE, Almagor D. Differences in adverse event reporting rates of therapeutic failure between two once-daily extended-release methylphenidate medications in Canada: analysis of spontaneous adverse event reporting databases. Clin Ther. 2017;39(10):2006–23.CrossRefPubMedGoogle Scholar
  6. 6.
    American Enterprise Institute. Dangerous drugs in your medicine cabinet? A whistleblower’s account of India’s troubling exports. 2013. Accessed 11 Dec 2017.
  7. 7.
    Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43(10):1583–97.CrossRefPubMedGoogle Scholar
  8. 8.
    Endrenyi L, Tothfalusi L. Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products? J Pharm Pharmaceut Sci Publ Can Soc Pharmaceut Sci Soc Can Des Sci Pharmaceut. 2010;13(1):107–13.Google Scholar
  9. 9.
    Moore TJ, Singh S, Furberg CD. The FDA and new safety warnings. Arch Internal Med. 2012;172(1):78–80.CrossRefGoogle Scholar
  10. 10.
    Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiol Drug Saf. 2016;25(6):713–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Iyer G, Marimuthu SP, Segal JB, Singh S. An algorithm to identify generic drugs in the FDA Adverse Event Reporting System. Drug Saf. 2017;40(9):799–808.CrossRefPubMedGoogle Scholar
  12. 12.
    Bohn J, Kortepeter C, Munoz M, Simms K, Montenegro S, Dal Pan G. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97(5):508–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Institute of Safe Medicine Practices. A critique of a key drug safety reporting system. 2015. Updated January 28, 2015. Accessed 11 Dec 2017
  14. 14.
    Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, et al. Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs. Drug Saf. 2017. (Epub ahead of print).PubMedGoogle Scholar
  15. 15.
    Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One. 2011;6(11):e27016.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    FDA. FDA Adverse Events Reporting System (FAERS) Public Dashboard: FDA; 2017. Accessed 11 Dec 2017
  17. 17.
    Marimuthu SP, Iyer G, Segal JB, Singh S. Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. J Comp Effect Res. 2017;6(5):437–47.CrossRefGoogle Scholar
  18. 18.
    Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157.CrossRefPubMedGoogle Scholar
  19. 19.
    Onasaya OIG, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diab Endocrinol. 2016;4(11):943–56.CrossRefGoogle Scholar
  20. 20.
    Alexander GCIG, Lucas E, Lin D, Singh S. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med. 2017;130(3):293–305.CrossRefPubMedGoogle Scholar
  21. 21.
    Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chang H-Y, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015;350:h1585.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tang W, Chang H-Y, Zhou M, Singh S. Risk of major gastrointestinal bleeding among dabigatran users: a population-based, new-user, self-controlled study. J Patient-Cent Re Rev. 2017;4(3):181.Google Scholar
  24. 24.
    Maruthur NM, Joy SM, Dolan JG, Shihab HM, Singh S. Use of the analytic hierarchy process for medication decision-making in type 2 diabetes. PLoS One. 2015;10(5):e0126625.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Westerhoff J. Nāgārjuna’s Madhyamaka. A philosophical introduction. Oxford: Oxford University Press; 2009.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Family Medicine and Community Health and Meyers Primary Care InstituteUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations